ArticleJournal of neurology2018
Depressive symptoms in stroke patients treated and non-treated with intravenous thrombolytic therapy: a 1-year follow-up study.
Article in Journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Depressive Symptoms After Mechanical Thrombectomy in Ischaemic Stroke: A Longitudinal Descriptive Study with Gender Differences.Healthcare (Basel, Switzerland) · 2026Article
- The mediating effects of hope on the relationships of social support and self-esteem with psychological resilience in patients with stroke.BMC psychiatry · 2024Article
- Post-Stroke Depression in Older Adults: An Overview.Drugs & aging · 2024Review
- Intravenous thrombolysis and risk of early-onset post-stroke depression: a propensity score matched cohort study.Frontiers in neurology · 2024Article
- Increased Risk of Developing Depression in Disability after Stroke: A Korean Nationwide Study.International journal of environmental research and public health · 2023Article
- The advances of post-stroke depression: 2021 update.Journal of neurology · 2022Review
- Development and Psychometric Properties of the Caregiver Burden Scale in Polish Caregivers of Stroke Patients.Psychology research and behavior management · 2022Article
- Microglia Involves in the Immune Inflammatory Response of Poststroke Depression: A Review of Evidence.Oxidative medicine and cellular longevity · 2022Review
- Does urinary metabolite signature act as a biomarker of post-stroke depression?Frontiers in psychiatry · 2022Review
- Neuroprotective Effect of Astragaloside IV on Cerebral Ischemia/Reperfusion Injury Rats Through Sirt1/Mapt Pathway.Frontiers in pharmacology · 2021Article
- UPLC-Q-TOF/MS-Based Serum Metabolomics Reveals the Anti-Ischemic Stroke Mechanism of Nuciferine in MCAO Rats.ACS omega · 2020Article
- Depressed Mood after Stroke: Predictive Factors at Six Months Follow-Up.International journal of environmental research and public health · 2020Observational
- Are Depression and Dementia a Common Problem for Stroke Older Adults? A Review of Chosen Epidemiological Studies.The Psychiatric quarterly · 2020Review
- Sanhua Decoction, a Classic Herbal Prescription, Exerts Neuroprotection Through Regulating Phosphorylated Tau Level and Promoting Adult Endogenous Neurogenesis After Cerebral Ischemia/Reperfusion Injury.Frontiers in physiology · 2020Article
- Contributing factors to quality of life after vertebral artery dissection: a prospective comparative study.BMC neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis is a prospective study, first to compare the frequency of depressive symptoms in stroke survivors treated, and non-treated, with intravenous thrombolysis and second, to explore relationships between post-stroke depression (PSD) and stroke treatment modalities, taking into account other possible determinants of PSD, including post-traumatic stress symptoms.
methodsGroups of 73 thrombolysed and 73 non-thrombolysed patients matched for age and gender were examined at 3 and 12 months after discharge. PSD was assessed using the Beck Depression Inventory. Post-traumatic stress symptoms (PTSS), disability and social support were assessed with the Impact of Event Scale-Revised, the Barthel Index and the Berlin Social Support Scale.
resultsAt 3 months, PSD was present in 23.3% of the thrombolysed and 31.5% in the non-thrombolysed groups (p = 0.265). At 12 months, the frequencies were 29.2 and 20.6% (p = 0.229). Logistic regression of the combined group of thrombolysed and non-thrombolysed patients indicated that at 3 months, the adjusted predictors of PSD were disability (OR 24.35), presence of PTSS (OR 9.32), low social support (OR 3.68) and non-thrombolytic treatment (OR 3.19). At 12 months, the predictors were disability (OR 15.78) and low education (OR 3.61). LIMITATIONS: The use of a questionnaire for the detection of depression, the relatively small sample size and a significant drop-out rate could limit the interpretation of these results.
conclusions(1) Thrombolysed and non-thrombolysed stroke survivors had similar frequency of depressive symptoms although the thrombolysed patients had more severe neurological deficits in the acute phase. It can be assumed that if thrombolysis had not been used, depressive symptoms would have been more frequent. (2) Lack of the rt-PA treatment was associated with three-time greater odds of screening for PSD at 3 months post-stroke, after adjustment for other PSD correlates. (3) Therefore, thrombolytic therapy seems to have a positive, but indirect, effect on patients' mood, especially in the first months after stroke. (4) All stroke patients, irrespective of the method of treatment, should be monitored for the presence of depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.